Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Cabazitaxel

Review the clinical trials studying cabazitaxel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-12 of 12

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy will Improve Outcomes Compared to Cabazitaxel Alone in People with Castrate-Resistant Prostate Cancer that has Spread Beyond the Prostate to Other Parts of the Body
Status: Active
Location: 447 locations
Targeted Treatment for Metastatic Prostate Cancer, PREDICT Trial
Status: Active
Location: 68 locations
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Status: Active
Location: 19 locations
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Status: Active
Location: 6 locations
Chemoimmunotherapy for the Treatment of Men with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer, CHAMP Study
Status: Active
Location: 3 locations
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Status: Active
Location: 3 locations
Omeprazole and Cabazitaxel for the Treatment of Docetaxel- and Castration- Resistant Prostate Cancer
Status: Active
Location: 2 locations
Carboplatin and Cabazitaxel versus Lutetium-177-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CATCH-177 Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Pegargiminase (ADI-PEG 20), Carboplatin, and Cabazitaxel for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Telmisartan Alone or Combined with Selected Standard of Care Therapy for the Treatment of Prostate Cancer
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Olaparib, Cabazitaxel, Carboplatin, and Prednisone in Treating Patients with Metastatic Prostate Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Status: Active
Location: See ClinicalTrials.gov